Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta

• Conditions: Chronic Hepatitis Delta; Liver Biopsy
• Interventions: Procedure: liver biopsy

• Registration Number: NCT04170452
• Lead Sponsor: Tokhirbek Dolimov

Brief Summary

Study the content of the HBV DNA in liver biopsy in the patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma

Detailed Description

Investigators interpreted the data of several researchers that studied suppression of the HBV DNA replication in the Delta infection within this article. Co-infection and superinfection of hepatitis B virus (HBV) with hepatitis delta virus (HDV) leads to suppression of HBV replication in both patients as well as animals and cell models. The mechanisms underlying this suppression were not fully studied before.

Jaw-Ching Wu et al. described the suppression of HBV DNA replication during HBV and HDV co-infection for the first time in 1991. The results of studies in the liver experimental models HuH-7 clearly demonstrated that one delta HDV antigen can suppress the expression of HBV RNA.

Dulce Alfaiate et al. conducted studies on the experimental models proving that HBV replication markers, including HBeAg, total HBV DNA and pregenomic RNA were significantly reduced after superinfection with HDV which confirming the effect of HDV on HBV. But thereby, the levels of circularly covalently closed levels of HBV DNA (cccDNA) and HBsAg were not decreased. At the peak of HDV-RNA accumulation and appearance of the interference in HBV replication, a strong I type IFN response was observed with highly induced genes stimulated by the interferon, RSAD2 (Viperin) and IFI78 (MxA). Both mono- and superinfected dHepaRG cells maintained strong intracellular replication of HDV, which was accompanied with the strong secretion of infectious HDV virions.

The following analysis of the data in the experimental studies by Zhenfeng Zhang et al. proved that the HDV virus activated strongly IFN-β and IFN-λ in the hepatocyte cell lines. The active HDV replication induces the IFN-β/λ response. Unlike hepatitis B virus, hepatitis D virus infection causes a strong IFN-β/λ response in the innate immunocompetent cell lines. The activated IFN did not suppress replication of hepatitis D virus in vitro, which indicatesthat Delta hepatitis virus is resistant to the self-induced innate immune responses and therapeutic treatment for IFN.

According to the authors, this stimulation of the synthesis of endogenous IFN-β and IFN-λ inside the hepatocyte by the HDV virus caused suppression of the HBV virus replication.

The following study, conducted Paolo Pugnale et al., in Huh-7 human hepatoma cells demonstrates that HDV can disrupt the IFN-α-stimulated JAK-STAT signaling pathway (a mediating protein ensuring cell response to the signals from the interleukin receptors and growth factors). The mechanism adopted by HDV to interfere with IFN-α/β signaling is based on inhibition of the tyrosine phosphorylation of STAT1, STAT2 and Tyk2 receptor-bound kinase without reducing expression levels of the IFN receptor subunits or other components in the signaling cascade. These results indicate that the HDV virus develops a strategy to counteract the actions of I type IFN. This study may be useful for a better understanding of the observed resistance to IFN in the chronic patients with the Chronic Hepatitis Delta and may provide the useful data for defining new strategies for antiviral intervention.

However, it should be noted that KatashibaY. in his research indicates that IFN is mainly stimulated in case of infection with the DNA-containing viruses, while IL-12 induction predominates in case of the RNA-containing infections. Since HDV consists of a single-stranded RNA molecule, it is not expected to stimulate IFN.

Given the above stated disagreements in the results of the authors' studies, Investigators decided to examine the patients with the Chronic Hepatitis Delta when the HBV DNA was not detected in the blood during examination by PCR.

Study Timeline

• Study Start: 2019-10-10
• Status Verified: 2019-11
• Study First Submitted: 2019-11-15
• Study First Submitted QC: 2019-11-19
• Last Update Submitted: 2019-11-19
• Study First Posted: 2019-11-20
• Last Update Posted: 2019-11-21
• Primary Completion: 2020-06-01
• Study Completion: 2020-06-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma

Exclusion Criteria

• patient's with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma but: inability to remain still and to maintain brief expiration for the procedure, suspected vascular lesion (eg, hemangioma), bleeding tendency (eg, INR > 1.2 despite receiving vitamin K, bleeding time > 10 min), severe thrombocytopenia (< 50,000/mL)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Chronic Hepatitis Delta patients	liver biopsy	Patients infected with delta virus

Primary Outcome Measures

Name	Time	Method
The study the content of the HBV DNA in liver biopsy	up to 3 months	In this study we are going to do liver biopsy in 30 patients with a diagnosis of Chronic Viral Hepatitis B and Delta.

Trial Locations

Locations (1)

RIEMID; 🇺🇿 Tashkent, Uchtepa District,, Uzbekistan